$OVID
Ovid Therapeutics Inc.

2022 Q4 Form 10-Q Financial Statement

#000162828022028772 Filed on November 08, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3
Revenue $46.28K $11.10K
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.663M $7.632M
YoY Change -19.72% 12.23%
% of Gross Profit
Research & Development $5.556M $5.183M
YoY Change -69.3% 5.41%
% of Gross Profit
Depreciation & Amortization $185.0K $102.1K
YoY Change 537.94%
% of Gross Profit
Operating Expenses $12.22M $12.81M
YoY Change -53.72% 9.7%
Operating Profit -$12.80M
YoY Change 9.61%
Interest Expense $1.068M $1.036M
YoY Change
% of Operating Profit
Other Income/Expense, Net -$400.0K -$200.0K
YoY Change
Pretax Income -$11.50M -$11.97M
YoY Change -56.26% 2.29%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$11.50M -$11.97M
YoY Change -55.75% 5.13%
Net Earnings / Revenue -24859.1% -107798.33%
Basic Earnings Per Share -$0.17
Diluted Earnings Per Share -$0.16 -$0.17
COMMON SHARES
Basic Shares Outstanding 70.47M shares 70.42M shares
Diluted Shares Outstanding 70.43M shares

Balance Sheet

Concept 2022 Q4 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $129.0M $137.9M
YoY Change -31.31% -31.69%
Cash & Equivalents $44.87M $58.26M
Short-Term Investments $84.13M $79.60M
Other Short-Term Assets $2.379M $2.640M
YoY Change -11.88% -19.99%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $131.4M $140.5M
YoY Change -31.03% -31.48%
LONG-TERM ASSETS
Property, Plant & Equipment $1.148M $1.160M
YoY Change 372.89% 1007.64%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $5.100M $5.100M
YoY Change 218.75% 218.75%
Other Assets $261.2K $275.4K
YoY Change 59.17% 39.72%
Total Long-Term Assets $23.89M $24.53M
YoY Change 487.49% 1108.64%
TOTAL ASSETS
Total Short-Term Assets $131.4M $140.5M
Total Long-Term Assets $23.89M $24.53M
Total Assets $155.3M $165.0M
YoY Change -20.19% -20.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.953M $1.033M
YoY Change -72.6% -67.11%
Accrued Expenses $4.505M $5.699M
YoY Change -41.28% -17.68%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.992M $6.732M
YoY Change -52.75% -33.11%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $16.00M $16.25M
YoY Change
Total Long-Term Liabilities $16.00M $16.25M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $6.992M $6.732M
Total Long-Term Liabilities $16.00M $16.25M
Total Liabilities $22.99M $22.98M
YoY Change 55.38% 128.34%
SHAREHOLDERS EQUITY
Retained Earnings -$225.5M -$214.0M
YoY Change 31.6% 47.18%
Common Stock $70.47K $356.2M
YoY Change -99.98% 4.02%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $132.3M $142.1M
YoY Change
Total Liabilities & Shareholders Equity $155.3M $165.0M
YoY Change -20.19% -20.31%

Cashflow Statement

Concept 2022 Q4 2022 Q3
OPERATING ACTIVITIES
Net Income -$11.50M -$11.97M
YoY Change -55.75% 5.13%
Depreciation, Depletion And Amortization $185.0K $102.1K
YoY Change 537.94%
Cash From Operating Activities -$9.176M -$12.68M
YoY Change -23.54% 16.3%
INVESTING ACTIVITIES
Capital Expenditures $63.00K -$18.60K
YoY Change -131.5%
Acquisitions
YoY Change
Other Investing Activities -$4.107M -$1.942M
YoY Change
Cash From Investing Activities -$4.170M -$1.960M
YoY Change 4069.51% 1860.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -43.60K 81.63K
YoY Change -143.6% -86.4%
NET CHANGE
Cash From Operating Activities -9.176M -12.68M
Cash From Investing Activities -4.170M -1.960M
Cash From Financing Activities -43.60K 81.63K
Net Change In Cash -13.39M -14.56M
YoY Change 11.57% 39.95%
FREE CASH FLOW
Cash From Operating Activities -$9.176M -$12.68M
Capital Expenditures $63.00K -$18.60K
Free Cash Flow -$9.239M -$12.66M
YoY Change -21.71% 16.13%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001636651
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Depreciation
Depreciation
187541 usd
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38085
dei Entity Registrant Name
EntityRegistrantName
Ovid Therapeutics Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-5270895
dei Entity Address Address Line1
EntityAddressAddressLine1
441 Ninth Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
14th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10001
dei City Area Code
CityAreaCode
646
dei Local Phone Number
LocalPhoneNumber
661-7661
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
OVID
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
70466885 shares
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
58257186 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
187797532 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
79600475 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
0 usd
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2640478 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2681597 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
140498139 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
190479129 usd
CY2022Q3 us-gaap Long Term Investments
LongTermInvestments
5951638 usd
CY2021Q4 us-gaap Long Term Investments
LongTermInvestments
1631992 usd
CY2022Q3 us-gaap Restricted Cash
RestrictedCash
1930253 usd
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
1930753 usd
CY2022Q3 us-gaap Security Deposit
SecurityDeposit
39091 usd
CY2021Q4 us-gaap Security Deposit
SecurityDeposit
96034 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1159657 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
242757 usd
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
15177639 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0 usd
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
275448 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
164092 usd
CY2022Q3 us-gaap Assets
Assets
165031865 usd
CY2021Q4 us-gaap Assets
Assets
194544757 usd
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1033066 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7127046 usd
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5699233 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7671275 usd
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
16248833 usd
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
0 usd
CY2022Q3 us-gaap Liabilities
Liabilities
22981132 usd
CY2021Q4 us-gaap Liabilities
Liabilities
14798321 usd
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
1 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
1 usd
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
70466885 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
70466885 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
70364912 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
70364912 shares
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
70467 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
70359 usd
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
356084810 usd
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
351033589 usd
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-82792 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-214021753 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-171357513 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
142050733 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
179746436 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
165031865 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
194544757 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
11102 usd
CY2021Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1456468 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
208382779 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5183253 usd
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4917393 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19062192 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28849969 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7631705 usd
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6764341 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
25769525 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
28970053 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
12814958 usd
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
11681734 usd
us-gaap Operating Expenses
OperatingExpenses
44831717 usd
us-gaap Operating Expenses
OperatingExpenses
57820022 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12803856 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-11681734 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-43375249 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
150562757 usd
CY2022Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
836085 usd
CY2021Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
2657 usd
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
711009 usd
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-49593 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11967771 usd
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11679077 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-42664240 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
150513164 usd
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.14
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-294829 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1678532 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-11967771 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-11384248 usd
us-gaap Net Income Loss
NetIncomeLoss
-42664240 usd
us-gaap Net Income Loss
NetIncomeLoss
148834632 usd
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.61
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.15
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.61
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70430554 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
67929894 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70408657 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
67282495 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
70430554 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
67929894 shares
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-12000000 usd
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
70408657 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
67848033 shares
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-11967771 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-11384248 usd
us-gaap Net Income Loss
NetIncomeLoss
-42664240 usd
us-gaap Net Income Loss
NetIncomeLoss
148834632 usd
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
7335 usd
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-82792 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11960436 usd
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11384248 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-42747032 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
148834632 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
179746436 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1324812 usd
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
33079 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-16108056 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
164996271 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1720217 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
109548 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
-90127 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-14588414 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
152147496 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1782043 usd
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
81629 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
7335 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-11967771 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
142050733 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
43631656 usd
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1320002 usd
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
150975 usd
CY2021Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
176007307 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
221109940 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1257344 usd
CY2021Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
130656 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-15788427 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
206709513 usd
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1161911 usd
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
534585 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-11384248 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
197021761 usd
us-gaap Net Income Loss
NetIncomeLoss
-42664240 usd
us-gaap Net Income Loss
NetIncomeLoss
148834632 usd
ovid Noncash Consideration Received In Licensing Agreement Transaction
NoncashConsiderationReceivedInLicensingAgreementTransaction
945366 usd
ovid Noncash Consideration Received In Licensing Agreement Transaction
NoncashConsiderationReceivedInLicensingAgreementTransaction
0 usd
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-125721 usd
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
0 usd
ovid Interest Income With Changes In Accrued Interest Included In Changes In Operating Assets And Liabilities
InterestIncomeWithChangesInAccruedInterestIncludedInChangesInOperatingAssetsAndLiabilities
-821024 usd
ovid Interest Income With Changes In Accrued Interest Included In Changes In Operating Assets And Liabilities
InterestIncomeWithChangesInAccruedInterestIncludedInChangesInOperatingAssetsAndLiabilities
0 usd
us-gaap Share Based Compensation
ShareBasedCompensation
4827072 usd
us-gaap Share Based Compensation
ShareBasedCompensation
3739258 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
327525 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
180128 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
614130 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
0 usd
ovid Accretion Of Lease Liability
AccretionOfLeaseLiability
650089 usd
ovid Accretion Of Lease Liability
AccretionOfLeaseLiability
0 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
156221 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
609244 usd
us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
56943 usd
us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
54592 usd
us-gaap Increase Decrease Due From Affiliates
IncreaseDecreaseDueFromAffiliates
0 usd
us-gaap Increase Decrease Due From Affiliates
IncreaseDecreaseDueFromAffiliates
-141763 usd
ovid Increase Decrease In Prepaid Expense Noncurrent
IncreaseDecreaseInPrepaidExpenseNoncurrent
0 usd
ovid Increase Decrease In Prepaid Expense Noncurrent
IncreaseDecreaseInPrepaidExpenseNoncurrent
-477171 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-6093980 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-2283479 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1972044 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-5109673 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-12382779 usd
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
0 usd
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-2432192 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-46051395 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
130610177 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
108857928 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
0 usd
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
30000000 usd
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
0 usd
us-gaap Net Income Loss
NetIncomeLoss
-42700000 usd
us-gaap Payments To Acquire Longterm Investments
PaymentsToAcquireLongtermInvestments
2500000 usd
us-gaap Payments To Acquire Longterm Investments
PaymentsToAcquireLongtermInvestments
1631992 usd
ovid Payments For Proceeds From Issuance Of Short Term Note Receivable
PaymentsForProceedsFromIssuanceOfShortTermNoteReceivable
1000000 usd
ovid Payments For Proceeds From Issuance Of Short Term Note Receivable
PaymentsForProceedsFromIssuanceOfShortTermNoteReceivable
0 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1104440 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
22050 usd
us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
251340 usd
us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
5400 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-83713708 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1659442 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
21314 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
168577 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
204678 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
55680 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
611538 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
224257 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
794902 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-129540846 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
129745637 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
189728285 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
72033930 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
60187439 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
201779567 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
15791769 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
ovid Conversion Of Short Term Note Receivable To Long Term Equity Investment
ConversionOfShortTermNoteReceivableToLongTermEquityInvestment
1000000 usd
ovid Conversion Of Short Term Note Receivable To Long Term Equity Investment
ConversionOfShortTermNoteReceivableToLongTermEquityInvestment
0 usd
CY2022Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
137900000 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
222500000 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-214000000 usd
CY2022Q3 ovid Working Capital
WorkingCapital
133800000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-46100000 usd
us-gaap Use Of Estimates
UseOfEstimates
Use of EstimatesThe preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ materially from those estimates.
CY2022Q3 us-gaap Equity Method Investments
EquityMethodInvestments
5100000 usd
CY2021Q4 us-gaap Equity Method Investments
EquityMethodInvestments
1600000 usd
CY2022Q1 us-gaap Land Subject To Ground Leases
LandSubjectToGroundLeases
19143 sqft
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
0 usd
CY2021Q4 ovid Cash Cash Equivalents And Available For Sale Debt Securities Amortized Cost
CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost
187797532 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 usd
CY2022Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
79683266 usd
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 usd
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
82792 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
79600474 usd
CY2022Q3 ovid Cash Cash Equivalents And Available For Sale Debt Securities Amortized Cost
CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost
137940453 usd
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 usd
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
82792 usd
CY2022Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
137857661 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
0 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0 usd
CY2021Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
187797532 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0 investment
CY2022Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0 investment
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
449750 usd
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
262208 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1159657 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
242757 usd
CY2022Q3 us-gaap Depreciation
Depreciation
102071 usd
CY2021Q3 us-gaap Depreciation
Depreciation
16497 usd
us-gaap Depreciation
Depreciation
52974 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
275448 usd
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
164092 usd
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
53348 usd
CY2021Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
35681 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
139984 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
127154 usd
CY2022Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P10Y
us-gaap Payments For Rent
PaymentsForRent
2300000 usd
CY2022Q1 ovid Lessee Operating Lease Rent Payments Commencement Following This Period
LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod
P10M
CY2022Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P10Y
CY2022Q1 ovid Lessee Operating Lease Free Rent Period
LesseeOperatingLeaseFreeRentPeriod
P2M
CY2022Q3 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P10Y
CY2022Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2022Q3 ovid Lease Incremental Borrowing Rate
LeaseIncrementalBorrowingRate
0.0702
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
15177639 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0 usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
16248833 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
1264219 usd
us-gaap Variable Lease Cost
VariableLeaseCost
0 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
0 usd
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3764666 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1672886 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2316303 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2316303 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2316303 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
2316303 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
12347235 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
23285333 usd
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3430534 usd
CY2022Q3 ovid Accrued Research And Development
AccruedResearchAndDevelopment
933050 usd
CY2021Q4 ovid Accrued Research And Development
AccruedResearchAndDevelopment
1795190 usd
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
500381 usd
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1564955 usd
CY2022Q3 ovid Income Tax Accrual Current
IncomeTaxAccrualCurrent
284536 usd
CY2021Q4 ovid Income Tax Accrual Current
IncomeTaxAccrualCurrent
0 usd
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
550732 usd
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
546464 usd
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5699233 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7671275 usd
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
ovid Common Stock Number Of Votes Per Share
CommonStockNumberOfVotesPerShare
1 vote
us-gaap Dividends
Dividends
0 usd
us-gaap Dividends
Dividends
0 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1782043 usd
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1161911 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4827072 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3739258 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1782043 usd
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1161911 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4827072 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3739258 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y7M17D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
56953 usd
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10776758 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.97
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y25D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2389890 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4555641 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.89
ovid Share Based Compensation By Share Based Payment Award Options Granted Contractual Life
ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife
P9Y6M3D
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
25518 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.91
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
2293622 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
5.63
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
13013259 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.13
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
5873500 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
5.30
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P6Y1M6D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
56192 usd
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
13000000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y4M20D
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2021Q4 ovid License Agreement Milestone Payments
LicenseAgreementMilestonePayments
203000000 usd
CY2022Q3 ovid Research And Development Arrangement Research Plan And Budget Expected Costs
ResearchAndDevelopmentArrangementResearchPlanAndBudgetExpectedCosts
3000000 usd
us-gaap Equity Securities Fv Ni Unrealized Loss
EquitySecuritiesFvNiUnrealizedLoss
100000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
144989259 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-11967771 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-11384248 usd
us-gaap Net Income Loss
NetIncomeLoss
-42664240 usd
us-gaap Net Income Loss
NetIncomeLoss
148834632 usd
CY2022Q3 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
0 usd
CY2021Q3 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
0 usd
us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
0 usd
us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
3845373 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11967771 usd
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11384248 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-42664240 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11967771 usd
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11384248 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-42664240 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
144989259 usd
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70430554 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
67929894 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70408657 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
67282495 shares
CY2022Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2021Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
565538 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
70430554 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
67929894 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
70408657 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
67848033 shares
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.61
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.15
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.61
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.14
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
13013259 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
13013259 shares

Files In Submission

Name View Source Status
0001628280-22-028772-index-headers.html Edgar Link pending
0001628280-22-028772-index.html Edgar Link pending
0001628280-22-028772.txt Edgar Link pending
0001628280-22-028772-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
ovid-20220930.htm Edgar Link pending
ovid-20220930.xsd Edgar Link pending
ovid-20220930_g1.jpg Edgar Link pending
ovid-2022q3xexx311.htm Edgar Link pending
ovid-2022q3xexx312.htm Edgar Link pending
ovid-2022q3xexx321.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
ovid-20220930_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
ovid-20220930_def.xml Edgar Link unprocessable
ovid-20220930_lab.xml Edgar Link unprocessable
ovid-20220930_pre.xml Edgar Link unprocessable
ovid-20220930_htm.xml Edgar Link completed
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending